Mill Creek Capital Advisors LLC Has $4.75 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Mill Creek Capital Advisors LLC has increased its stake in Thermo Fisher Scientific by 14.4%, owning 9,542 shares valued at approximately $4.75 million.
• Several institutional investors have adjusted their positions, with Vanguard Group increasing its holdings by 0.7%, now owning 33.48 million shares worth nearly $16.66 billion.
• Thermo Fisher Scientific recently announced a quarterly dividend of $0.43 per share, with a yield of 0.4%, payable on October 15th.

Mill Creek Capital Advisors LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,542 shares of the medical research company's stock after purchasing an additional 1,202 shares during the quarter. Mill Creek Capital Advisors LLC's holdings in Thermo Fisher Scientific were worth $4,748,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Freestone Capital Holdings LLC grew its holdings in shares of Thermo Fisher Scientific by 4.5% during the 1st quarter. Freestone Capital Holdings LLC now owns 27,364 shares of the medical research company's stock valued at $13,616,000 after acquiring an additional 1,167 shares in the last quarter. Corient IA LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at about $249,000. George Kaiser Family Foundation purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $255,000. Northwest & Ethical Investments L.P. grew its stake in shares of Thermo Fisher Scientific by 44.5% in the 1st quarter. Northwest & Ethical Investments L.P. now owns 27,758 shares of the medical research company's stock valued at $13,812,000 after buying an additional 8,542 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Thermo Fisher Scientific by 1.3% in the first quarter. Steward Partners Investment Advisory LLC now owns 33,163 shares of the medical research company's stock worth $16,502,000 after buying an additional 414 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $11.3820 on Thursday, reaching $483.4280. 1,360,161 shares of the company were exchanged, compared to its average volume of 2,488,745. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The stock's fifty day moving average price is $439.69 and its 200 day moving average price is $458.78. The firm has a market capitalization of $182.55 billion, a PE ratio of 27.96, a PEG ratio of 2.66 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the company earned $5.37 earnings per share. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $52,037,916.68. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,896 shares of company stock valued at $8,593,838. Corporate insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on TMO shares. Royal Bank Of Canada decreased their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Barclays increased their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday. They issued an "outperform" rating for the company. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.